Unicycive Therapeutics (NASDAQ:UNCY) Now Covered by Analysts at B. Riley Financial

B. Riley Financial began coverage on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a report issued on Friday morning, Marketbeat reports. The firm issued a buy rating and a $22.00 price objective on the stock.

A number of other brokerages also recently weighed in on UNCY. Guggenheim lowered their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Westpark Capital began coverage on Unicycive Therapeutics in a research note on Thursday, February 19th. They set a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th. Finally, Benchmark lowered their price objective on Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating for the company in a research note on Monday, April 6th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.75.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ UNCY traded up $0.01 during trading on Friday, reaching $7.67. The stock had a trading volume of 483,336 shares, compared to its average volume of 493,929. Unicycive Therapeutics has a one year low of $3.71 and a one year high of $11.00. The stock has a market cap of $193.59 million, a PE ratio of -3.53 and a beta of 1.78. The firm’s 50 day moving average price is $6.88 and its two-hundred day moving average price is $6.18.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.36). On average, research analysts expect that Unicycive Therapeutics will post 1.12 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC bought a new position in Unicycive Therapeutics during the 2nd quarter worth $55,000. JPMorgan Chase & Co. boosted its position in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after acquiring an additional 21,525 shares during the period. Quadrature Capital Ltd acquired a new position in Unicycive Therapeutics during the 4th quarter worth $226,000. Citadel Advisors LLC acquired a new position in Unicycive Therapeutics during the 3rd quarter worth $182,000. Finally, State Street Corp boosted its position in Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after acquiring an additional 10,400 shares during the period. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.